Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 452

1.

Torasemide significantly reduces thiazide-induced potassium and magnesium loss despite supra-additive natriuresis.

Knauf H, Mutschler E, Velazquez H, Giebisch G.

Eur J Clin Pharmacol. 2009 May;65(5):465-72. doi: 10.1007/s00228-009-0626-7. Epub 2009 Feb 20.

PMID:
19229529
2.

Pharmacology of intracellular cytosine-arabinoside-5'-triphosphate in malignant cells of pediatric patients with initial or relapsed leukemia and in normal lymphocytes.

Koehl U, Hollatz G, Rohrbach E, Visschedyk K, Cinatl J, Kornhuber B, Kreuter J, Mutschler E, Schwabe D.

Cancer Chemother Pharmacol. 2007 Sep;60(4):467-77. Epub 2006 Dec 14.

PMID:
17171362
3.

[In].

Mutschler E, Schubert-Zsilavecz M.

Pharm Unserer Zeit. 2006;35(6):471. German. No abstract available.

PMID:
17137074
4.

The influence of cardiovascular and antiinflammatory drugs on thiazide-induced hemodynamic and saluretic effects.

Knauf H, Bailey MA, Hasenfuss G, Mutschler E.

Eur J Clin Pharmacol. 2006 Nov;62(11):885-92. Epub 2006 Sep 9.

PMID:
16964522
5.

[Sequential nephron blockade].

Knauf H, Mutschler E.

Pharm Unserer Zeit. 2006;35(4):334-40. Review. German. No abstract available.

PMID:
16886509
6.

[Pharmacology of diuretics].

Knauf H, Mutschler E.

Pharm Unserer Zeit. 2006;35(4):302-9. Review. German. No abstract available.

PMID:
16886506
7.

In vivo non-linear intestinal permeability of celiprolol and propranolol in conscious dogs: evidence for intestinal secretion.

Lipka E, Spahn-Langguth H, Mutschler E, Amidon GL.

Eur J Pharm Sci. 1998 Jan;6(1):75-81.

PMID:
16256710
8.

Rate-limiting biotransformation of triamterene is mediated by CYP1A2.

Fuhr U, Kober S, Zaigler M, Mutschler E, Spahn-Langguth H.

Int J Clin Pharmacol Ther. 2005 Jul;43(7):327-34.

PMID:
16035375
10.

[Fixed combination of inhalant steroids and long-acting beta(2) agonists].

Petermann W, Mutschler E.

Dtsch Med Wochenschr. 2004 Jan 30;129(5):210-4. Review. German. No abstract available.

PMID:
14735419
11.

[Drug interactions. Mechanisms and clinical relevance].

Klotz U, Beil W, Gleiter C, Drewelow B, Garbe E, Gillessen A, Mutschler E.

Internist (Berl). 2003 Nov;44(11):1444-9. Review. German.

PMID:
14689079
12.

GERD 2003 -- a consensus on the way ahead.

Moss SF, Armstrong D, Arnold R, Ferenci P, Fock KM, Holtmann G, McCarthy DM, Moraes-Filho JP, Mutschler E, Playford R, Spechler SJ, Stanghellini V, Modlin IM.

Digestion. 2003;67(3):111-7. Review.

13.

Pharmacokinetics and bioavailability of denaverine hydrochloride in healthy subjects following intravenous, oral and rectal single doses.

Staab A, Schug BS, Larsimont V, Elze M, Thümmler D, Mutschler E, Blume H.

Eur J Pharm Sci. 2003 Feb;18(2):121-8.

PMID:
12594004
14.

Structure-activity relationships of dimethindene derivatives as new M2-selective muscarinic receptor antagonists.

Böhme TM, Keim C, Kreutzmann K, Linder M, Dingermann T, Dannhardt G, Mutschler E, Lambrecht G.

J Med Chem. 2003 Feb 27;46(5):856-67.

PMID:
12593665
15.

[Living collegenin and collagen].

Mutschler E, Schubert-Zsilavecz M.

Pharm Unserer Zeit. 2003;32(1):5. German. No abstract available.

PMID:
12577752
16.

Determination of triamterene and its main metabolite hydroxytriamterene sulfate in human urine by capillary electrophoresis using ultraviolet absorbance and laser-induced fluorescence detection.

Horstkötter C, Kober S, Spahn-Langguth H, Mutschler E, Blaschke G.

J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Mar 25;769(1):107-17.

PMID:
11936683
17.
18.

[Risk factors in hypertension: a disease with fatal consequences].

Mutschler E, Schubert-Zsilavecz M.

Pharm Unserer Zeit. 2001;30(4):279. German. No abstract available.

PMID:
11499247
19.

[AIDS--a disease we must be prepared to treat].

Mutschler E, Dingermann T.

Pharm Unserer Zeit. 2001;30(3):181. German. No abstract available.

PMID:
11400659
20.

The influence of age on the pharmacokinetics and pharmacodynamics of bemetizide and triamterene: a single and multiple dose study.

Mühlberg W, Mutschler E, Hofner A, Spahn-Langguth H, Arnold O.

Arch Gerontol Geriatr. 2001 Jun;32(3):265-73.

PMID:
11395172
21.

Design and pharmacology of quinuclidine derivatives as M2-selective muscarinic receptor ligands.

Böhme TM, Keim C, Dannhardt G, Mutschler E, Lambrecht G.

Bioorg Med Chem Lett. 2001 May 7;11(9):1241-3.

PMID:
11354386
22.

A validated high-performance liquid chromatographic assay for the simultaneous determination of denaverine and its N-monodemethyl metabolite in human plasma.

Staab A, Scheithauer S, Fieger-Büschges H, Mutschler E, Blume H.

J Chromatogr B Biomed Sci Appl. 2001 Feb 25;751(2):221-8.

PMID:
11236077
23.

Vitamins C and E protect isolated cardiomyocytes against oxidative damage.

Rinne T, Mutschler E, Wimmer-Greinecker G, Moritz A, Olbrich HG.

Int J Cardiol. 2000 Sep 15;75(2-3):275-81.

PMID:
11077146
24.

Comparative pharmacodynamics and pharmacokinetics of candesartan and losartan in man.

Fuchs B, Breithaupt-Grögler K, Belz GG, Roll S, Malerczyk C, Herrmann V, Spahn-Langguth H, Mutschler E.

J Pharm Pharmacol. 2000 Sep;52(9):1075-83.

PMID:
11045887
25.

Gemfibrozil and its oxidative metabolites: quantification of aglycones, acyl glucuronides, and covalent adducts in samples from preclinical and clinical kinetic studies.

Hermening A, Gräfe AK, Baktir G, Mutschler E, Spahn-Langguth H.

J Chromatogr B Biomed Sci Appl. 2000 May 12;741(2):129-44.

PMID:
10872583
26.

The novel heteromeric bivalent ligand SB9 potently antagonizes P2Y(1) receptor-mediated responses.

Lambrecht G, Ganso M, Bäumert HG, Spatz-Kümbel G, Hildebrandt C, Braun K, Mutschler E.

J Auton Nerv Syst. 2000 Jul 3;81(1-3):171-7.

PMID:
10869717
27.
28.

Muscarinic properties of compounds related to arecaidine propargyl ester.

Tumiatti V, Wehrle J, Hildebrandt C, Moser U, Dannhardt G, Mutschler E, Lambrecht G.

Arzneimittelforschung. 2000 Jan;50(1):11-5.

PMID:
10683710
29.

The novel pyridoxal-5'-phosphate derivative PPNDS potently antagonizes activation of P2X(1) receptors.

Lambrecht G, Rettinger J, Bäumert HG, Czeche S, Damer S, Ganso M, Hildebrandt C, Niebel B, Spatz-Kümbel G, Schmalzing G, Mutschler E.

Eur J Pharmacol. 2000 Jan 17;387(3):R19-21.

PMID:
10650184
30.
31.

Novel ligands for P2 receptor subtypes in innervated tissues.

Lambrecht G, Damer S, Niebel B, Czeche S, Nickel P, Rettinger J, Schmalzing G, Mutschler E.

Prog Brain Res. 1999;120:107-17.

PMID:
10550991
32.
33.

Current status of sustained release formulations in the treatment of hypertension. An overview.

Mutschler E, Knauf H.

Clin Pharmacokinet. 1999;37 Suppl 1:1-6. Review.

PMID:
10491727
34.

Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged.

Fliser D, Bischoff I, Hanses A, Block S, Joest M, Ritz E, Mutschler E.

Eur J Clin Pharmacol. 1999 May;55(3):205-11.

PMID:
10379636
35.

Blue native PAGE as a useful method for the analysis of the assembly of distinct combinations of nicotinic acetylcholine receptor subunits.

Nicke A, Rettinger J, Mutschler E, Schmalzing G.

J Recept Signal Transduct Res. 1999 Jan-Jul;19(1-4):493-507.

PMID:
10071780
36.
37.

Coadministration of albumin and furosemide in patients with the nephrotic syndrome.

Fliser D, Zurbrüggen I, Mutschler E, Bischoff I, Nussberger J, Franek E, Ritz E.

Kidney Int. 1999 Feb;55(2):629-34.

38.

Intracellular pH regulation in bovine aortic endothelial cells: evidence of both Na+/H+ exchange and Na+-dependent Cl-/HCO3- exchange.

Faber S, Lang HJ, Hock FJ, Schölkens BA, Mutschler E.

Cell Physiol Biochem. 1998;8(4):202-11.

39.

NF279: a novel potent and selective antagonist of P2X receptor-mediated responses.

Damer S, Niebel B, Czeche S, Nickel P, Ardanuy U, Schmalzing G, Rettinger J, Mutschler E, Lambrecht G.

Eur J Pharmacol. 1998 May 29;350(1):R5-6.

PMID:
9683026
40.

Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man.

Malerczyk C, Fuchs B, Belz GG, Roll S, Butzer R, Breithaupt-Grögler K, Herrmann V, Magin SG, Högemann A, Voith B, Mutschler E.

Br J Clin Pharmacol. 1998 Jun;45(6):567-73.

41.

P2X1 and P2X3 receptors form stable trimers: a novel structural motif of ligand-gated ion channels.

Nicke A, Bäumert HG, Rettinger J, Eichele A, Lambrecht G, Mutschler E, Schmalzing G.

EMBO J. 1998 Jun 1;17(11):3016-28.

42.
43.

Beta-blockade as an alternative to cardioplegic arrest during cardiopulmonary bypass.

Warters RD, Allen SJ, Davis KL, Geissler HJ, Bischoff I, Mutschler E, Mehlhorn U.

Ann Thorac Surg. 1998 Apr;65(4):961-6.

PMID:
9564910
45.

Clinical pharmacokinetics and pharmacodynamics of torasemide.

Knauf H, Mutschler E.

Clin Pharmacokinet. 1998 Jan;34(1):1-24. Review.

PMID:
9474471
46.

Evidence for muscarinic M4 receptors mediating nonadrenergic noncholinergic relaxations in rabbit anococcygeus muscle.

Gross J, Mutschler E, Lambrecht G.

Naunyn Schmiedebergs Arch Pharmacol. 1997 Oct;356(4):505-16.

PMID:
9349639
47.

Characterization of postjunctional muscarinic receptors mediating contraction in rat anococcygeus muscle.

Weiser M, Mutschler E, Lambrecht G.

Naunyn Schmiedebergs Arch Pharmacol. 1997 Nov;356(5):671-7.

PMID:
9402048
48.

Low-dose reserpine/thiazide combination in first-line treatment of hypertension: efficacy and safety compared to an ACE inhibitor.

Griebenow R, Pittrow DB, Weidinger G, Mueller E, Mutschler E, Welzel D.

Blood Press. 1997 Sep;6(5):299-306.

PMID:
9360001
49.

Pharmacokinetics and pharmacodynamics of triamterene and hydrochlorothiazide and their combination in healthy volunteers.

Möhrke W, Knauf H, Mutschler E.

Int J Clin Pharmacol Ther. 1997 Oct;35(10):447-52.

PMID:
9352394
50.

Inhibition of angiotensin II pressor response and ex vivo angiotensin II radioligand binding by candesartan cilexetil and losartan in healthy human volunteers.

Belz GG, Fuchs B, Malerczyk C, Magin SG, Roll S, Mutschler E.

J Hum Hypertens. 1997 Sep;11 Suppl 2:S45-7. No abstract available.

PMID:
9331006

Supplemental Content

Loading ...
Support Center